In vitro effects of vandetanib on VEGFR2, EGFR and RET phosphorylation, endothelial cell tube formation, and tumor cell growth and survival

Eitemau Tebyg

• Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer.
  gan: Brave, SR, et al.
  Cyhoeddwyd: (2011)
• A secondary RET mutation in the activation loop conferring resistance to vandetanib
  gan: Takashi Nakaoku, et al.
  Cyhoeddwyd: (2018-02-01)
• A phase I dose escalation study of the tolerability of the oral VEGFR and EGFR inhibitor vandetanib in combination with the oral MEK1/2 inhibitor selumetinib in solid tumors
  gan: Pacey, S, et al.
  Cyhoeddwyd: (2016)
• Deciphering the resistance mechanism of RET kinase mutant against vandetanib and nintedanib using molecular dynamics simulations
  gan: Guodong Zheng, et al.
  Cyhoeddwyd: (2021-12-01)
• Evaluating vandetanib in the treatment of medullary thyroid cancer: patient-reported outcomes
  gan: Fallahi P, et al.
  Cyhoeddwyd: (2019-08-01)